...going to be. To me, what's intriguing is, what kind of story can you put together from a health economic perspective of reducing disease burden, hospitalization costs, and everything else?"
— Thomas Hess, a principal at Avalere Health in vaccine policy
and commercialization, spoke with AIS's RADAR
on Drug Benefits about Merck's COVID-19 drug and its chances at
scoring an FDA emergency use nod.
No comments:
Post a Comment